GP210 Antibody, IgG, Serum
Use
Evaluating the risk of primary biliary cholangitis in anti-mitochondrial antibody (AMA)-negative patients by identification of gp210 antibodies. Estimating risk in AMA-positive patients with incomplete feature of disease. Primary biliary cholangitis (PBC) is a chronic and progressive autoimmune liver disease characterized by the destruction of small intrahepatic bile ducts and a variable clinical course.
Special Instructions
This is a first line test when primary biliary cholangitis is strongly suspected. This test should be ordered in conjunction with testing for mitochondrial antibodies (M2), SP100 antibodies, and antinuclear antibodies.
Limitations
The presence of primary biliary cholangitis (PBC)-specific autoantibodies, including anti-gp210, should not be relied upon exclusively to make a diagnosis of PBC or predict disease outcome. A negative result for anti-gp210 antibodies does not exclude a diagnosis of PBC. Results should be used in conjunction with clinical findings and other serological tests.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 96560-8
- 96560-8
Result Turnaround Time
2-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Heat-treated specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |